Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of L9LS for Malaria Prevention in Mali
NCT05304611Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2022
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of L9LS in malaria (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Participants With Local Adverse Events (AEs) - Year One at 7 days, Participants With Systemic Adverse Events (AEs) - Year One at 7 days and 3 more. Started Mar 2022; status: completed.
02
Drugs
L9LS
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05304611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304611.